Skip to main content

Table 3 Step 1. Survival in association with patients’ SEP adjusted for treatment, patients’ and disease characteristics

From: Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

Main components Model 1.0 (M1.0) Model 1.1 Model 1.2 Model 1.3 Model 1.4 Model 1.5 Model 1.6 M 1.7
M1.0 + perf. Status M1.0 + AML ont M1.0 + WBC. M1.0 + cyto. Progn. M1.0 + treatment All but treatment Fully adjusted
HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI]
Age 1.04 [1.03; 1.05] 1.03 [1.02; 1.05] 1.04 [1.03; 1.05] 1.04 [1.03; 1.05] 1.04 [1.02; 1.05] 1.01 [1.00; 1.03] 1.03 [1.02; 1.05] 1.02 [1.00; 1.03]
Sex Men ref   ref   ref   ref     ref   Ref   ref  
Women 0.88 [0.73; 1.07] 0.86 [0.71; 1.04] 0.87 [0.72; 1.05] 0.89 [0.74; 1.08] 0.84 [0.69; 1.01] 0.87 [0.72; 1.05] 0.81 [0.67; 0.98] 0.82 [0.68; 1.00]
Patients’ SEP (quintile of deprivation score) Q1 – least ref   Ref   Ref   Ref     Ref   ref   Ref  
Q2 1.14 [0.85; 1.53] 1.11 [0.83; 1.50] 1.08 [0.80; 1.45] 1.17 [0.87; 1.35] 1.06 [0.79; 1.42] 1 [0.84; 1.50] 1.01 [0.75; 1.37] 0.96 [0.71; 1.29]
Q3 0.89 [0.67; 1.18] 0.85 [0.64; 1.13] 0.83 [0.62; 1.11] 0.88 [0.66; 1.17] 0.89 [0.67; 1.18] 0.84 [0.69; 1.22] 0.80 [0.60; 1.07] 0.78 [0.58; 1.04]
Q4 1.07 [0.82; 1.40] 1.02 [0.78; 1.33] 1.03 [0.79; 1.35] 1.07 [0.82; 1.40] 1.06 [0.81; 1.38] 1 [0.82; 1.40] 0.99 [0.75; 1.30] 0.94 [0.71; 1.24]
Q5 – most 1.39 [1.04; 1.87] 1.37 [1.02; 1.84] 1.31 [0.97; 1.76] 1.47 [1.10; 1.97] 1.30 [0.97; 1.75] 1.35 [1.12; 2.01] 1.28 [0.95; 1.73] 1.29 [0.95; 1.74]
Charlson comorbidity index 0 ref   ref   ref   ref     ref   ref   ref  
1 1.1 [0.86; 1.41] 1.02 [0.80; 1.31] 1.08 [0.85; 1.38] 1.15 [0.90; 1.47] 1.09 [0.86; 1.40] 1.01 [0.79; 1.29] 1.07 [0.83; 1.37] 1.00 [0.78; 1.28]
2+ 1.29 [1.01; 1.66] 1.18 [0.92; 1.52] 1.21 [0.94; 1.56] 1.3 [1.01; 1.66] 1.35 [1.06; 1.73] 1.13 [0.88; 1.45] 1.19 [0.92; 1.54] 1.08 [0.83; 1.41]
Undefined 2.1 [1.60; 2.76] 1.89 [1.39; 2.56] 1.88 [1.40; 2.53] 2.06 [1.56; 2.73] 1.97 [1.49; 2.61] 1.29 [0.96; 1.74] 1.66 [1.20; 2.31] 1.25 [0.89; 1.75]
Performance status 0/1    ref            Ref   ref  
2    1.51 [1.16; 1.97]           1.49 [1.15; 1.95] 1.50 [1.15; 1.95]
3/4    2.36 [1.70; 3.28]           1.90 [1.34; 2.68] 1.72 [1.22; 2.42]
Undefined    1.75 [1.24; 2.48]           1.52 [1.04; 2.20] 1.29 [0.88; 1.88]
AML ontogeny AML de novo      ref          Ref   ref  
Secondary AML (post treatment / MDS)   1.25 [1.03; 1.52]         1.21 [0.99; 1.48] 1.12 [0.91; 1.38]
Undefined       1.56 [0.90; 2.72]         1.60 [0.90; 2.83] 1.52 [0.86; 2.70]
White blood cell (WBC) counts (tercile) Tercile 1 – low           ref          Ref  
Terticle 2 – intermediate        1.42 [1.10; 1.83]       1.38 [1.06; 1.79] 1.34 [1.04; 1.74]
Terticle 3 – high        2.24 [1.66; 3.01]       2.16 [1.59; 2.93] 2.36 [1.74; 3.20]
Undefined           2.9 [1.50; 5.60]       2.28 [1.14; 4.56] 2.10 [1.05; 4.21]
Cytogenetic prognosis Favorable/Intermediate                     
Unfavorable              2.00 [1.64; 2.43]     2.01 [1.64; 2.46] 1.72 [1.38; 2.13]
Undefinable              1.99 [1.34; 2.96]     1.88 [1.24; 2.86] 1.44 [0.95; 2.18]
Treatment Intensive chemotherapy              ref       
Low intensive therapy              1.53 [1.19; 1.96]    1.36 [1.01; 1.82]
Best supportive care              4.11 [2.93; 5.77]    3.24 [2.21; 4.76]
Time varying component                    
Time * Performance status 0.9998 [0.9997;0.9999]            0.9999 [0.9998; 1.0000] 0.9999 [0.9998; 1.0000]
Time * White blood cell counts        0.9993 [0.9990; 0.9996]    0.9993 [0.9989; 0.9996] 0.9992 [0.9990; 0.9996]
  1. Adjusted hazard ratios [95% Confidence Intervals] of overall mortality from Adjusted Cox proportional hazards model with time dependent variables (n = 592)